A phase III Equivalence Trial of PF 582 for the Treatment of Macular Degeneration (AMD)

Trial Profile

A phase III Equivalence Trial of PF 582 for the Treatment of Macular Degeneration (AMD)

Planning
Phase of Trial: Phase III

Latest Information Update: 09 May 2016

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Wet age-related macular degeneration
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 09 May 2016 According to a Pfenex media release, the company is planning to initiate this trial in the second half of 2016.
    • 16 Mar 2015 According to Pfenex media release, company is planning to initiate this trial in 2016.
    • 12 Feb 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top